HIF-1α and STAT3 are important transcription factors activated by low oxygen levels and play key roles in cancer processes like cell survival and growth.
Overexpression of these factors is common in many human cancers, making them attractive targets for new cancer drugs.
The study presents a new compound, P3971, which effectively inhibits both HIF-1α and STAT3, showing strong anti-cancer activity in lab tests and in animal models for colon and lung cancers.
The study presents the development of new furoquinoline-based molecules (compounds 16-36) and their effectiveness in inhibiting the PI3K/Akt signaling pathway and mTOR, demonstrated through both cell-based and cell-free assays.
Compound 23 stands out for not only inhibiting the PI3K-mTOR pathway but also for significantly reducing the levels of HIF-1alpha protein in hypoxic conditions, particularly in U251-HRE cells.
The effectiveness of compound 23 was validated through Western blot analysis on human non-small cell lung carcinoma H-460 cells and glioblastoma U251 cells.